Athersys, Inc. (NASDAQ:ATHX) insider William Lehmann, Jr. sold 30,000 shares of the stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $2.25, for a total value of $67,500.00. Following the completion of the transaction, the insider now directly owns 460,084 shares in the company, valued at approximately $1,035,189. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Athersys traded down $0.01, reaching $2.01, on Thursday, Marketbeat reports. 5,305 shares of the company traded hands, compared to its average volume of 1,355,759. Athersys, Inc. has a 52 week low of $1.29 and a 52 week high of $3.09. The stock has a market capitalization of $284.20 million, a P/E ratio of -6.93 and a beta of -0.79.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. Athersys had a negative return on equity of 119.58% and a negative net margin of 1,112.74%. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.17 million. research analysts expect that Athersys, Inc. will post -0.24 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in ATHX. SG Americas Securities LLC bought a new position in shares of Athersys during the fourth quarter valued at about $108,000. Northern Trust Corp grew its stake in shares of Athersys by 7.1% during the first quarter. Northern Trust Corp now owns 1,215,690 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 80,708 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Athersys by 214.9% during the first quarter. JPMorgan Chase & Co. now owns 69,370 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 47,339 shares during the last quarter. 16.87% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently commented on ATHX shares. Maxim Group started coverage on Athersys in a research note on Monday, April 23rd. They issued a “buy” rating and a $6.00 target price on the stock. Zacks Investment Research cut Athersys from a “buy” rating to a “hold” rating in a research note on Wednesday, April 18th. BidaskClub raised Athersys from a “hold” rating to a “buy” rating in a research note on Saturday, May 19th. Finally, ValuEngine cut Athersys from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.